C07D 515/22
In which the condensed system contains four or more hetero rings
Official title: in which the condensed system contains four or more hetero rings
C07D515/22 (In which the condensed system contains four or more hetero rings) appears on 59 US grants and 106 published applications in this corpus.
Search patents in C07D- Granted patents
- 59
- Published applications
- 106
- Assignees
- 64
- Inventors
- 377
- Latest grant
- 9 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1979 | 1 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 1 | 0 |
| 2000 | 1 | 0 |
| 2001 | 1 | 0 |
| 2002 | 0 | 1 |
| 2003 | 0 | 2 |
| 2004 | 1 | 4 |
| 2005 | 1 | 1 |
| 2006 | 1 | 6 |
| 2007 | 3 | 3 |
| 2008 | 3 | 5 |
| 2009 | 1 | 7 |
| 2010 | 6 | 2 |
| 2011 | 5 | 0 |
| 2012 | 2 | 0 |
| 2013 | 0 | 3 |
| 2014 | 0 | 2 |
| 2015 | 0 | 2 |
| 2016 | 4 | 2 |
| 2017 | 3 | 3 |
| 2018 | 2 | 2 |
| 2019 | 2 | 2 |
| 2020 | 2 | 0 |
| 2021 | 2 | 6 |
| 2022 | 5 | 11 |
| 2023 | 2 | 20 |
| 2024 | 4 | 8 |
| 2025 | 2 | 7 |
| 2026 | 2 | 7 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Macrocyclic compounds, compositions, and methods of using thereof9 Jun 2026US 12,649,750 B2Genzyme Corporation
- Macrocyclic compounds, compositions, and methods of using thereof12 May 2026US 12,624,051 B2Genzyme Corporation
- Antitumoral compounds12 Aug 2025US 12,384,800 B2Pharma Mar, S. A.
- Macrocyclic fused pyrazoles as Mcl-1 inhibitors3 Jun 2025US 12,319,703 B2Ascentage Pharma Group Corp Limited
- Preparation method for ecteinascidin compound and intermediate thereof22 Oct 2024US 12,122,784 B2BrightGene Bio-Medical Technology Co., Ltd.
- Macrocyclic compounds as usp1 inhibitors24 Sep 2026US 2026/0285876 A1Guangdong Newopp Biopharmaceuticals Co., Ltd.
- Novel compounds and uses thereof13 Aug 2026US 2026/0234163 A1Acelink Therapeutics, Inc.
- Ecteinascidin derivative antibody drug conjugates6 Aug 2026US 2026/0224720 A1Adcytherix SAS
- Proteolysis targeting chimera compound30 Jul 2026US 2026/0217730 A1Beijing Tide Pharmaceutical Co., Ltd.
- Lurbinectedin crystal form and method for preparing same21 May 2026US 2026/0138992 A1Shanghai Haoyuan Chemexpress Co., Ltd.
Most cited
By later US patents
- Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith44US 5,256,663 AThe Board of Trustees of the University of Illinois · 1993
- Ecteinascidins 736 and 72237US 5,149,804 AThe Board of Trustees of the University of Illinois · 1992
- Nucleophile substituted ecteinascidins and N-oxide ecteinascidins33US 5,985,876 A1999
- Semi-synthetic ecteinascidins30US 6,124,293 AThe Board of Trustees of the University of Illinois · 2000
- ETM-775 metabolite of ecteinascidin 74329US 6,316,214 B1The Board of Trustees of the University of Illinois · 2001